These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 11953432)
1. Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation. Kohn EA; Ruth ND; Brown MK; Livingstone M; Eastman A J Biol Chem; 2002 Jul; 277(29):26553-64. PubMed ID: 11953432 [TBL] [Abstract][Full Text] [Related]
2. Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest. Levesque AA; Fanous AA; Poh A; Eastman A Mol Cancer Ther; 2008 Feb; 7(2):252-62. PubMed ID: 18281511 [TBL] [Abstract][Full Text] [Related]
3. Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G2 cell cycle checkpoints. Levesque AA; Kohn EA; Bresnick E; Eastman A Oncogene; 2005 May; 24(23):3786-96. PubMed ID: 15782134 [TBL] [Abstract][Full Text] [Related]
4. A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01. Eastman A; Kohn EA; Brown MK; Rathman J; Livingstone M; Blank DH; Gribble GW Mol Cancer Ther; 2002 Oct; 1(12):1067-78. PubMed ID: 12481430 [TBL] [Abstract][Full Text] [Related]
5. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. Graves PR; Yu L; Schwarz JK; Gales J; Sausville EA; O'Connor PM; Piwnica-Worms H J Biol Chem; 2000 Feb; 275(8):5600-5. PubMed ID: 10681541 [TBL] [Abstract][Full Text] [Related]
6. Regulation of Cdc2/cyclin B activation in Xenopus egg extracts via inhibitory phosphorylation of Cdc25C phosphatase by Ca(2+)/calmodulin-dependent protein [corrected] kinase II. Hutchins JR; Dikovskaya D; Clarke PR Mol Biol Cell; 2003 Oct; 14(10):4003-14. PubMed ID: 14517314 [TBL] [Abstract][Full Text] [Related]
7. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Shao RG; Cao CX; Shimizu T; O'Connor PM; Kohn KW; Pommier Y Cancer Res; 1997 Sep; 57(18):4029-35. PubMed ID: 9307289 [TBL] [Abstract][Full Text] [Related]
8. Abrogation of Chk1-mediated S/G2 checkpoint by UCN-01 enhances ara-C-induced cytotoxicity in human colon cancer cells. Shao RG; Cao CX; Pommier Y Acta Pharmacol Sin; 2004 Jun; 25(6):756-62. PubMed ID: 15169628 [TBL] [Abstract][Full Text] [Related]
9. UCN-01 induces S and G2/M cell cycle arrest through the p53/p21(waf1) or CHK2/CDC25C pathways and can suppress invasion in human hepatoma cell lines. Wu G; Lin N; Xu L; Liu B; Feitelson MA BMC Cancer; 2013 Mar; 13():167. PubMed ID: 23537372 [TBL] [Abstract][Full Text] [Related]
10. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Hirose Y; Berger MS; Pieper RO Cancer Res; 2001 Aug; 61(15):5843-9. PubMed ID: 11479224 [TBL] [Abstract][Full Text] [Related]
11. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe. Tse AN; Schwartz GK Cancer Res; 2004 Sep; 64(18):6635-44. PubMed ID: 15374978 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of cyclin-dependent kinase 2 by the Chk1-Cdc25A pathway during the S-phase checkpoint activated by fludarabine: dysregulation by 7-hydroxystaurosporine. Sampath D; Shi Z; Plunkett W Mol Pharmacol; 2002 Sep; 62(3):680-8. PubMed ID: 12181445 [TBL] [Abstract][Full Text] [Related]
13. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Yu Q; La Rose J; Zhang H; Takemura H; Kohn KW; Pommier Y Cancer Res; 2002 Oct; 62(20):5743-8. PubMed ID: 12384533 [TBL] [Abstract][Full Text] [Related]
14. Chk1 instability is coupled to mitotic cell death of p53-deficient cells in response to virus-induced DNA damage signaling. Jurvansuu J; Fragkos M; Ingemarsdotter C; Beard P J Mol Biol; 2007 Sep; 372(2):397-406. PubMed ID: 17663993 [TBL] [Abstract][Full Text] [Related]
15. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Busby EC; Leistritz DF; Abraham RT; Karnitz LM; Sarkaria JN Cancer Res; 2000 Apr; 60(8):2108-12. PubMed ID: 10786669 [TBL] [Abstract][Full Text] [Related]
16. UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation. Sugiyama K; Shimizu M; Akiyama T; Tamaoki T; Yamaguchi K; Takahashi R; Eastman A; Akinaga S Int J Cancer; 2000 Mar; 85(5):703-9. PubMed ID: 10699952 [TBL] [Abstract][Full Text] [Related]
17. Dual regulation of Cdc25A by Chk1 and p53-ATF3 in DNA replication checkpoint control. Demidova AR; Aau MY; Zhuang L; Yu Q J Biol Chem; 2009 Feb; 284(7):4132-9. PubMed ID: 19060337 [TBL] [Abstract][Full Text] [Related]
18. p53-dependent Chk1 phosphorylation is required for maintenance of prolonged G2 Arrest. Wang XQ; Stanbridge EJ; Lao X; Cai Q; Fan ST; Redpath JL Radiat Res; 2007 Dec; 168(6):706-15. PubMed ID: 18088187 [TBL] [Abstract][Full Text] [Related]
19. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. Wang Q; Fan S; Eastman A; Worland PJ; Sausville EA; O'Connor PM J Natl Cancer Inst; 1996 Jul; 88(14):956-65. PubMed ID: 8667426 [TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy of 7-hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines. Lee SI; Brown MK; Eastman A Biochem Pharmacol; 1999 Dec; 58(11):1713-21. PubMed ID: 10571245 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]